P soriasis is a chronic immune-mediated disease affecting up to 3% of the population. 1 Skin and joint inflammation are the hallmarks of psoriasis and an increase in the number of T lymphocytes, antigen presenting cells, macrophages, and neutrophils is found in psoriatic plaques. 2 The complex interplay between inflammatory cells and keratinocytes induces epidermal proliferation resulting in the typical indurated, scaly, and erythematous plaques of psoriasis. 3 Psoriasis has been shown to increase the risk of myocardial infarction and stroke. [4] [5] [6] [7] Psoriasis treatments include topical corticosteroids, vitamin D analogs and phototherapy and also systemic anti-inflammatory agents, such as methotrexate, cyclosporin, or biological agents targeting tumor necrosis factor-α (TNF-α) or interleukin (IL)-12/IL-23. 8 These systemic agents all have a profound effect on skin and joint inflammation.
blinded to treatment assignment), randomized, parallel group and active-controlled study (clinicaltrials.gov NTC00940862). Declaration of Helsinki protocols were followed; the study protocol was approved by the Montreal Heart Institute institutional review board, and written informed consent was obtained from each patient. Eligible patients were 18 to 80 years of age with chronic, moderate to severe plaque type psoriasis covering a minimum of 5% of the body surface area who were candidates for systemic therapy. In addition, patients had to have either a history of coronary atherosclerosis (defined as having at least 1 narrowing of the diameter of the arterial lumen of ≥50% on coronary angiography, previous myocardial infarction, previous coronary revascularization, abnormal radionuclide myocardial perfusion scan, or abnormal stress echocardiogram) or a minimum of 3 risk factors among the following: hypertension, active smoking, diabetes mellitus, dyslipidemia, obesity, microalbuminuria, age >55 years, and first degree relative with evidence of coronary atherosclerosis <65 years. Patients were also required to show a carotid artery or ascending aorta target:background ratio (TBR) of ≥1.6 as determined by 18 F-fludeoxyglucose (FDG) uptake measured by PET as evidence of atherosclerotic plaque inflammation. Patients taking medications for angina, hypertension, dyslipidemia, or other agents that could have an effect on inflammation must have been on a stable dose for ≥8 weeks before baseline. Patients were excluded if they had a myocardial infarction or hospitalization for a cardiac condition within 12 weeks of baseline; if they had used nonbiological systemic therapy for the treatment of psoriasis <30 days before day 0, biological therapy for the treatment of psoriasis <90 days before day 0, phototherapy or topical treatment for psoriasis within the last 2 weeks before baseline.
Patients were seen at the dermatology research clinic from May 2009 to June 2011 and were randomized (2:1) to either the TNFα antagonist adalimumab 10 or the control group using a concealed computer-generated code created by the sponsor. Adalimumab was administered subcutaneously with a loading dose of 80 mg followed by 40 mg, 1 week later and every other week thereafter up to and including week 15. Patients in the control group could use any topical psoriasis treatment, ultraviolet B phototherapy, or no treatment. Psoriasis severity was evaluated at each visit using the psoriasis area and severity index (PASI). 11 Fasting serum lipids and high-sensitivity C-reactive protein (hs-CRP) were analyzed at a local laboratory (CDL laboratories, Montreal, Canada).
PET/CT Image Acquisition
Details of imaging procedures and analyses have been published previously. 12 PET/CT imaging was performed at the Montreal Heart Institute after an overnight fast using a GE Healthcare (Milwaukee, WI) Discovery ST PET/CT scanner. Fasting serum glucose levels were checked by fingerstick to assure glucose levels <11.1 mmol/L before FDG administration. FDG-PET/CT scans of the carotid arteries and ascending thoracic aorta were performed ≈10 days before baseline and at week 15. Subjects were injected with 10 mCi of 18 F-FDG. Care was taken to ensure that imaging was performed at the same time interval (2 hours) after FDG injection for serial scans, to limit variability in FDG accumulation and background activity. After a 30-second scout, CT scan was acquired (140 kV, 80 mA, 4.25 mm slice thickness) for coregistration and attenuation correction; a 2-dimensional chest PET scan was performed from the aortic arch to the diaphragm. The scan was reconstructed using the OSEM algorithm with corrections applied for normalization, dead time, random events, scatter, attenuation, and sensitivity. A 3-dimensional PET/CT scan of the neck was acquired after stabilizing the neck in a holder to minimize movement and after setting the upper landmark to the superior portion of the auditory meatus in the scout view. This scan was reconstructed using the FORE-IT (iterative reconstruction of Fourier rebinning) with standard parameters.
PET/CT Image Analysis
Image analysis was performed using ITKsnap version 2.2.0 (GNU General public license) and in-house software developed using MATLAB 2010a (Natick, MA). An experienced reader (F.H.) analyzed all scans. All PET/CT measurements were performed at the end of the study, with core laboratory personnel and physician blinded to the randomization assignment. Using the CT images for coregistration, areas of interest were identified on PET scan images of the ascending aorta, right and left carotid arteries. Arterial FDG uptake was quantified by drawing a region of interest around each artery on every slice of the coregistered PET/CT images. The maximal arterial standardized uptake value (SUV) was then calculated as the maximal pixel activity within the region of interest of every slice of the vessel. The mean SUV was also calculated for every slice. The maximum and mean SUVs were measured along the carotid arteries and ascending aorta at ≈5 mm intervals, in axial orientation. The SUV is calculated as a time-corrected concentration of tissue radioactivity in kilobecquerels per mL, adjusted for the injected FDG dose and the body weight of the patient, and is a widely used method for quantification of FDG-PET data. The maximal and mean arterial TBR were then calculated by dividing the maximum and mean arterial SUVs by the blood (background) SUV, the latter estimated from the superior vena cavae (for the ascending aorta TBR) and jugular veins (for carotid artery TBR) to produce a blood (background)-corrected artery SUV. This is considered to be a reflection of arterial FDG uptake. For evaluation of the mean FDG blood pool uptake, at least six 3-to 4-mm region of interests were placed in consecutive slices of both jugular veins and superior vena cavae and averaged.
Study Outcomes
The primary end point was the change in the average of maximum TBR values (MeanMAX TBR) of carotid arteries and ascending aorta from baseline to week 15, analyzed in the vessel with highest baseline TBR. Secondary end points included the change in the average of the mean TBR values and the change in the most diseased segment from baseline to week 15 in the vessel with the highest baseline value. Most diseased segment TBR was defined as the 1.5 cm segment that demonstrated the highest PET/CT activity at baseline and was calculated as the MeanMax TBR values derived from 3 contiguous axial segments. The changes in TBR values were also analyzed separately in the carotid arteries and in the ascending aorta.
Changes in hs-CRP and serum lipids (total cholesterol, low-density lipoprotein-cholesterol, high-density lipoprotein-cholesterol, triglycerides), which were all secondary end points, were calculated from baseline to week 16. The proportion of patients reaching 75% improvement in PASI (PASI 75) at week 16 was also evaluated.
Statistical Methods
Because of the exploratory nature of this study, the sample size of 30 patients was not based on formal power calculations. Changes from baseline in PET/CT end points were studied using an ANOVA model adjusting for the baseline value of the end point. Changes from baseline are presented as least square mean estimates and SE. A repeated measures ANCOVA adjusting for baseline was used for the secondary end points of hs-CRP and lipid values. The proportion of patients reaching PASI 75 was compared using a χ 2 test. For all end points, the analysis was conducted on the intent to treat (ITT) population, and for the last observation carried forward method for missing data were used except for the PASI 75 end point, where a nonresponder imputation method was used. Sensitivity analyses were also performed on the ITT population with complete cases (for the primary end point) and a per-protocol population (for primary and secondary end points). All analyses were performed using SAS version 9.2 (SAS Institute, Inc., Cary, NC) with a significance level of 0.05 and prespecified in the statistical analysis plan.
Results

Patient Disposition and Baseline Characteristics
Thirty patients were enrolled in this study and included in the ITT analysis ( Figure 1 ). Baseline characteristics of patients are shown in Table 1 . All patients completed the study except 1 who died of a myocardial infarction after week 8. Seven patients were excluded from the perprotocol analysis; 4 started a new medication, and 3 had a dose change in medication that could influence vascular inflammation.
PET/CT Vascular Results
For the primary end point of change at week 15 in Mean-MAX TBR in the vessel with the highest baseline TBR, the change was significant in the adalimumab group (-0.23±0.07, P=0.004) but not in the control group (-0.10±0.11, P=0. 35) . The difference of least square means among groups did not reach statistical significance (-0.13±0.13, P=0.32). The same conclusion was reached when the analysis was performed using the Wilcoxon rank-sum test (P=0.695). Sensitivity analyses performed on the per-protocol population and the ITT population with complete cases supported the primary analysis of the ITT population (not shown).
The change (differences of least square means among groups) at week 15 in MeanMAX TBR improved with adalimumab compared with the control group both in the ascending aorta (-0.26±0.11; P=0.021 versus control, Figure 2A ) and in carotid arteries (-0.32±0.15; P=0.037 versus control, Figure  2B ). The changes in average of the mean TBR values and the change in most diseased segment TBR also improved with adalimumab compared with the control group in the ascending aorta and in carotid arteries, as shown in Table 2 (P=0.010, 0.011, 0.030, and 0.080, respectively). Representative PET/CT images of changes over time in patients of the adalimumab and control groups are shown in Figure 3 .
Psoriasis Evaluation
The proportion of patients who had at least PASI 75 at week 16 was 70% for patients randomized to adalimumab as compared with 20% for patients in the control group (P=0.01). This difference was also statistically significant when analyzed with Fisher exact test (not shown).
hs-CRP and Serum Lipids
hs-CRP levels were significantly decreased in patients randomized to adalimumab compared with those in patients randomized to the control group at days 28, 56, and 112 (P=0.013, 0.008, and 0.002, respectively; Figure 4) . The results were supported by those in the per-protocol population (not shown). There were no statistically significant changes over time in serum lipids ( Figure 5 ). There was no statistically significant difference between the 2 groups. *Mean±SD. HDL indicates high-density lipoprotein; hs-CRP, high-sensitivity c-reactive protein; LDL, low-density lipoprotein; MeanMAX, average of maximum values; PASI, psoriasis area severity index, PET/CT, positron emission tomography/ computed tomography; and TBR, target:background ratio.
Safety
There were 2 serious adverse events reported; 1 death caused by myocardial infarction, and 1 incidence of lithium toxicity. Both occurred in patients randomized to adalimumab and were deemed to be not related to the study drug by the investigator.
Discussion
This study showed that patients with moderate to severe psoriasis both in the active treatment and control arms had a change in MeanMAX TBR from baseline, and the difference across groups was not significant for the primary end point. However, patients treated for 15 weeks with adalimumab had a statistically significant decrease in vascular inflammation as measured by the change in MeanMAX TBR in the vessel with the highest baseline TBR, whereas the reduction was not significant in the control group (local therapy). The differences between adalimumab and control for MeanMAX TBR, most diseased segment TBR, and average of the mean TBR values were significant both in the carotid arteries and the ascending aorta when evaluated separately (secondary end points). The small sample size of 30, with only 10 patients in the control group, combined with the choice of vessel with highest TBR as primary end point may be responsible for the fact that the primary end point was not met. Selection of the vessel with the highest baseline inflammation may partially explain the nonsignificant decrease observed in the control group, because higher baseline values usually tend to regress to the mean. Using the observed distribution, the measured change from baseline in TBR and the 2:1 randomization scheme used in the current trial, a sample size of 306 patients would have been required to detect a statistically significant difference for the primary end point. Adalimumab also resulted in a reduction of plasma levels of hs-CRP as early as 4 weeks after initiation of treatment, and the effect lasted until the end of the study at 16 weeks. Finally, patients treated with adalimumab had a substantial improvement in psoriasis. The response rate is almost identical to what has been observed in the pivotal phase III study with adalimumab where 71% of patients achieved PASI 75. 10 Atherosclerosis is an inflammatory disease [13] [14] [15] [16] [17] [18] [19] and patients with different clinical atherosclerotic manifestations are faced with persistent vascular risk despite our current armamentarium. Anti-inflammatory therapies are presently being assessed to reduce further the risk of myocardial infarction and stroke of patients with established vascular disease. Inflammatory diseases, such as psoriasis and rheumatoid arthritis, are now known to expose patients to an increased risk of myocardial infarction and stroke. [4] [5] [6] [7] Psoriasis is a complex multi-systemic disease influenced by environmental and genetic factors. It is characterized by expansion of Th1, Th17, and Th22 cells resulting in significant inflammation at the skin and joint levels. 2 The expression of several cytokines, including TNF-α, interferon-γ, IL-17, IL-22, IL-23, is increased in the skin of patients with psoriasis. Inflammation is a hallmark of psoriasis, and cardiovascular risks have been shown to be higher in patients with more severe cutaneous disease. 7 Systemic inflammation is also increased in patients with psoriasis as shown by elevated levels of hs-CRP, but correlation between hs-CRP and myocardial infarction has not been well studied in this patient population. Whether treating patients with moderate to severe psoriasis with an
Baseline
Week 15 anti-inflammatory biological agent could reduce vascular inflammation and future vascular events (myocardial infarctions and strokes) is not known. Some studies based on claims databases or registries have suggested that treatment of rheumatoid arthritis or psoriasis with methotrexate or TNF-α antagonists could decrease the risks of myocardial infarction and stroke, whereas others have not been able to detect a significant risk difference. [20] [21] [22] [23] [24] [25] [26] In contrast, a nonstatistically significant increase in major cardiovascular events was observed when patients with psoriasis were treated with antibodies targeting IL-12 and IL-23 compared with placebo. 27 Before assessing the value of a TNF-α antagonist, such as adalimumab, on hard vascular events in a large prospective randomized placebo-controlled study, we first evaluated its effects on vascular inflammation as assessed with 18F-radiolabeled fluorodeoxyglucose ( 18 F-FDG) uptake on PET/CT imaging in a study with a positive control arm. FDG-PET is a sensitive and reproducible noninvasive technique to measure inflammation based on the accumulation of 18 F-FDG in inflamed atherosclerotic plaques. 15,28-30 18 F-FDG has been used to image metabolically active macrophages and inflammation. The uptake of 18 F-FDG has been shown to correlate with the extent of macrophage infiltration in carotid plaques of patients scheduled for carotid endarterectomy. 31 Carotid inflammation as detected by FDG-PET has been shown to be associated with cardiovascular risk factors. 32 FDG-PET has shown a reduction in plaque metabolic activity in large arteries after statin therapy in a small cohort of patients who were not preselected for the presence of vascular disease. 33 More recently, FDG-PET imaging was also used to evaluate the effects on vascular inflammation of the highdensity lipoprotein-raising drug dalcetrapib in patients with atherosclerosis. 12 In the current study, patients in the control group could be treated with any topical medication or ultraviolet B. There was a numeric decrease in the primary end point (MeanMAX TBR in the vessel with the highest baseline TBR) in the control group. Of note, the patient who had the largest and most prominent decrease in TBR (0.87) for the primary end point was treated with a superpotent topical corticosteroid and had a 97% decrease in PASI (almost complete skin response). It has been suggested that inflammation in the skin may increase inflammation in atherosclerotic plaques by the release from skin of activated T cells and cytokines, such as IL-1, IL-6, and TNF-α, in circulation. 2 This raises the intriguing and testable hypothesis that reduction of cutaneous inflammation using a local treatment, such as a very potent topical corticosteroid or ultraviolet B, may decrease vascular inflammation.
Control
The PET/CT results obtained with adalimumab are concordant with reduced hs-CRP levels, as well as the improvement of skin lesions observed in this study group. We, however, did not observe significant correlations between PET/CT findings and hs-CRP levels or PASI improvement (results not shown). The decrease in hs-CRP level was 51% at the end of study for patients randomized to adalimumab compared with 5% for patients in the control group. Higher hs-CRP levels have previously been shown to be associated with a higher risk of myocardial infarction and stroke. 34, 35 A study where psoriatic patients with an unsatisfactory response to other agents were switched to adalimumab reported a decrease of hs-CRP from 2.1 to 0.3 mg/L but did not include a control group, did not report statistical analysis on hs-CRP data, and included patients who had recently been treated with systemic agents for psoriasis. 36 Vascular FDG-PET imaging used in this study did not reflect major changes in systemic inflammation (hs-CRP) or clinical improvement (PASI) in psoriasis treated with the TNF-α antagonist adalimumab. Possible explanations for this discrepancy include the small study size, the relatively short study duration (4 months), the lack of prospective power calculation, and the potential that vascular inflammation measured by FDG uptake may differ from systemic inflammation in psoriasis. The clinical significance of reduced vascular inflammation on PET/CT imaging and hs-CRP levels is uncertain and would need to be determined in a large randomized trial evaluating the effects of adalimumab on cardiovascular clinical outcomes.
In conclusion, the study did not meet its primary end point as the change in TBR in patients randomized to adalimumab was not different from controls. Although adalimumab may reduce vascular inflammation in patients with moderate to severe psoriasis, this effect is not large enough to be demonstrated in a study with a small sample size. The differences between adalimumab and control for secondary PET/ CT end points, however, were significant both in the carotid arteries and the ascending aorta. Vascular FDG-PET imaging did not reflect major changes in hs-CRP levels with adalimumab, which may have been because of the small study size or differences between vascular and systemic inflammation in psoriasis.
